Yesafili, available in vial and prefilled syringe presentations (2 mg/0.05 mL), was the first biosimilar to Eylea approved by Health Canada
The goal is to deliver greater value to customers, doctors, and the broader healthcare ecosystem
Collaboration matches more eligible patients, including those with rare and complex diseases, to appropriate clinical trials
Pegozafermin offers a distinct mechanism of action with potential for enhanced efficacy and tolerability and opportunities for combination development with incretins
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Merck opens first climate-neutral manufacturing facility in Ireland
The inspection concluded with zero form 483 observations
The lab will facilitate the development of herbal and natural-based solutions
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
Subscribe To Our Newsletter & Stay Updated
